Indaptus Therapeutics, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Indaptus Therapeutics, Inc. (INDP) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$1.24 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2024-05-08
- Indaptus Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2024-03-31 was -$1.24M.
- Indaptus Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-12-31 was $408.26K, a 28.47% decline year-over-year.
- Indaptus Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-09-30 was $261.44K.
- Indaptus Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-06-30 was $280.00K.
- Indaptus Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$680.52K.
- Indaptus Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$1.15M.
- Indaptus Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2021 was -$4.24M, a 3819.63% decline from fiscal 2020.
- Indaptus Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2020 was $113.90K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2024-03-31 | -$1.24M 10-Q · filed 2024-05-08 | -$829.23K derived: sum of 2 quarters · filed 2024-05-08 | -$567.80K derived: sum of 3 quarters · filed 2024-05-08 | -$287.79K derived: sum of 4 quarters · filed 2024-05-08 | |
| 2023-12-31 | $408.26K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $669.70K derived: sum of 2 quarters · filed 2024-03-13 | $949.71K derived: sum of 3 quarters · filed 2024-03-13 | -$680.52K 10-K · filed 2024-03-13 | |
| 2023-09-30 | $261.44K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $541.44K derived: sum of 2 quarters · filed 2023-11-06 | -$1.09M 10-Q · filed 2023-11-06 | -$518.02K derived: sum of 4 quarters · filed 2024-05-08 | |
| 2023-06-30 | $280.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$1.35M 10-Q · filed 2023-08-14 | -$779.46K derived: sum of 3 quarters · filed 2024-05-08 | -$1.52M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2023-03-31 | -$1.63M 10-Q · filed 2024-05-08 | -$1.06M derived: sum of 2 quarters · filed 2024-05-08 | -$1.80M derived: sum of 3 quarters · filed 2024-05-08 | -$1.86M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | $570.76K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$173.19K derived: sum of 2 quarters · filed 2024-03-13 | -$229.63K derived: sum of 3 quarters · filed 2024-03-13 | -$1.15M 10-K · filed 2024-03-13 | |
| 2022-09-30 | -$743.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$800.39K derived: sum of 2 quarters · filed 2023-11-06 | -$1.73M 10-Q · filed 2023-11-06 | -$3.00M derived: sum of 4 quarters · filed 2023-11-06 | |
| 2022-06-30 | -$56.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$981.64K 10-Q · filed 2023-08-14 | -$2.25M derived: sum of 3 quarters · filed 2023-08-14 | -$5.05M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | -$925.20K 10-Q · filed 2023-05-11 | -$2.20M derived: sum of 2 quarters · filed 2023-05-11 | -$4.99M derived: sum of 3 quarters · filed 2023-05-11 | -$5.64M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$4.07M derived: sum of 2 quarters · filed 2023-03-17 | -$4.72M derived: sum of 3 quarters · filed 2023-03-17 | -$4.24M 10-K · filed 2023-03-17 | |
| 2021-09-30 | -$2.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$3.45M derived: sum of 2 quarters · filed 2022-11-10 | -$2.96M 10-Q · filed 2022-11-10 | -$3.20M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$650.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$169.22K 10-Q · filed 2022-08-08 | $72.00K 10-Q · filed 2021-08-16 | -$403.56K derived: sum of 3 quarters · filed 2022-08-08 | $3.91M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $481.05K 10-Q · filed 2022-05-12 | $246.71K derived: sum of 2 quarters · filed 2022-05-12 | $4.56M derived: sum of 3 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$234.34K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $4.08M derived: sum of 2 quarters · filed 2022-03-21 | $113.90K 10-K · filed 2022-03-21 | ||
| 2020-09-30 | $4.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $348.24K 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | -$3.96M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |